Caffeine is associated with improved alveolarization and angiogenesis in male mice following hyperoxia induced lung injury

Vikramaditya Dumpa, Lori Nielsen, Huamei Wang and Vasantha H. S. Kumar

Abstract

Background: Caffeine therapy for apnea of prematurity reduces the incidence of bronchopulmonary dysplasia (BPD) in premature neonates. Several mechanisms, including improvement in pulmonary mechanics underly beneficial effects of caffeine in BPD. As vascular development promotes alveologenesis, we hypothesized that caffeine might enhance angiogenesis in the lung, promoting lung growth, thereby attenuating BPD.

Methods: C57Bl/6 mice litters were randomized within 12 h of birth to room air (RA) or 95%O2 to receive caffeine (20 mg/kg/day) or placebo for 4 days and recovered in RA for 12wks. The lung mRNA and protein expression for hypoxia-inducible factors (HIF) and angiogenic genes performed on day 5. Lung morphometry and vascular remodeling assessed on inflation fixed lungs at 12wks.

Results: Caffeine and hyperoxia in itself upregulate HIF-2α and vascular endothelial growth factor gene expression. Protein expression of HIF-2α and VEGFR1 were higher in hyperoxia/caffeine and angiopoietin-1 lower in hyperoxia. An increase in radial alveolar count, secondary septal count, and septal length with a decrease in mean linear intercept indicate an amelioration of hyperoxic lung injury by caffeine. An increase in vessel surface area and a significant reduction in smooth muscle thickness of the pulmonary arterioles may suggest a beneficial effect of caffeine on vascular remodeling in hyperoxia, especially in male mice.

Conclusions: Postnatal caffeine by modulating angiogenic gene expression early in lung development may restore the pulmonary microvasculature and alveolarization in adult lung.

Keywords: Caffeine, Newborn, Mice, VEGF, Hypoxia-inducible factors, Lung, Hyperoxia

Background

Bronchopulmonary dysplasia (BPD), a form of chronic lung disease is a common cause of morbidity and mortality in extremely premature infants. Multiple factors are implicated in the pathogenesis of BPD including chorioamnionitis, oxygen toxicity, mechanical ventilation, and sepsis [1]. Irrespective of the pathogenesis, impaired alveolarization, and dysregulated angiogenesis are the defining characteristics of BPD [2]. Increased risk for asthma, related respiratory hospitalizations, and poor neuro-developmental outcomes are some of the long-term morbidities associated with BPD [3, 4].

Caffeine therapy in very low birth weight (VLBW) infants decreases BPD [5] and improves survival without neurodevelopmental disability at 18-month follow-up in these infants [6]. However, caffeine had no effect on the primary outcome of death or survival with a severe disability when the children were 5 years of age [7]. Caffeine treatment in premature infants not only reduces apnea of prematurity and recurrent hypoxic episodes in infants [8] but also reduces lung injury and improves respiratory function in children [9].
Caffeine is a nonspecific adenosine receptor antagonist. Adenosine is a purine nucleoside-signaling molecule with effects on regulating fibrosis, angiogenesis, and inflammation. Caffeine is thought to modulate TGF-β signaling [10], decrease inflammation [11] or attenuate endoplasmic stress [12] in protecting the lung from hyperoxia-induced lung injury [12, 13]. However, several studies have suggested an adverse role for caffeine in lung development [10, 14]. Although the molecular mechanisms underlying prevention of BPD with caffeine are uncertain, the potential beneficial effects could include antagonist effects of the adenosine receptor subtypes, A1, A2a, A2B, and A3 [15]. Adenosine promotes angiogenesis and regulates the expression of vascular endothelial growth factor (VEGF) through the adenosine receptors in different cell types [16, 17] and the regulation of hypoxia-inducible factor (HIF) pathway [16, 18, 19]. Recent studies suggest that disruption of VEGF function plays a pivotal role in the pathogenesis of BPD [20, 21]. Hypoxia-inducible factor-1 regulates the expression of genes encoding vascular development, with VEGF and angiopoietins being the important ones [22, 23]. HIF-1 expression is tightly linked to the oxygen concentration in vivo and hyperoxia or even normoxia in the developing lung rapidly induce HIF degradation and hence, VEGF expression [24]. The effects of caffeine on the developing lung vasculature in premature infants are not determined. A caffeine loading dose of 20 mg/kg would be approximately equivalent to 14–16 cups of coffee, and the maintenance dose (5 – 10 mg/kg) equivalent to 4–8 cups of coffee in an adult. Given these high doses over prolonged periods, our objective was to study whether caffeine modulates the HIF-1α/angiogenesis pathway contributing to an improvement in lung alveolarization. Lungs of adult mice exposed to hyperoxia as newborns are simplified and exhibit reduced function much like that observed in children with BPD as infants [25]. We investigate the effects of caffeine administration on angiogenesis and lung morphometry in newborn mice exposed to hyperoxia, a lung injury model similar to BPD in premature infants.

Methods
The Institution Animal Care and Use Committee of the University at Buffalo (Project # PED24116N- Current) approved all experimental protocols before the study. Time-dated pregnant C57Bl/6 mice were acclimatized in the lab animal facility after purchasing from the vendor (Envigo RMS Inc., Indianapolis, IN) before delivery. Dams were observed on the day of expected delivery for delivery of new litters with minimal disturbance. To minimize litter-dependent bias, all pups from different litters were distributed randomly between dams (5–6 pups/dam) within 12 h of birth into four groups: hyperoxia-caffeine (HC), room air-caffeine (RAC), hyperoxia-saline (HS) and room air-saline (RAS) groups (3–4 litters/group; Minimum of 18 pups/group). Litters were exposed to hyperoxia (95% O2) for 96 h from Day 1 to Day 4 (HS/HC) or to room air (RAS/RAC) to serve as controls. Oxygen exposures were performed in a large Plexiglas chamber monitored for temperature, oxygen concentration (95%O2 or 21%O2), and humidity (50–60%). We alternated dams between hyperoxia and room air-exposed litters every 24 h to prevent maternal oxygen toxicity. Mice in the room air group were subjected to the same environment as the hyperoxia group. All pups were weighed at birth and every day after that. Caffeine citrate (20 mg/mL; Fresenius Kabi, Lake Zurich, IL) was administered at a dose of 20 mg/kg/day for mice randomized to the caffeine groups (RAC/HC groups) or an equivalent volume of normal saline for mice randomized to saline (RAS/HS groups) by intraperitoneal injection. All doses were administered at the same time (10 AM to Noon) once every 24 h for four doses. Mice were sacrificed 24 h after the last treatment of caffeine on postnatal day 5 with an intraperitoneal injection of sodium pentobarbital. Gene expression, protein, and cytokine analysis were performed in mice sacrificed on Day 5 in all the four groups (eight mice/group). In the second part of the experiment, mice recovered in room air following 96 h of hyperoxia and postnatal caffeine for 12 weeks until sacrifice. Lungs were formalin fixed at 12 weeks in all groups (ten mice/group).

RNA isolation
RNA was isolated from flash frozen mouse lung using RNeasy mini kit (Qiagen, Valencia, CA) with on-column DNase digestion per manufacturer’s protocol. RNA integrity was assessed using the Experion Automated Electrophoresis System (Biorad, Hercules, CA).

Real-time quantitative PCR
Genes of the hypoxia-inducible factor (HIF) pathway (HIF-1α, HIF-2α, HIF-3α, HIF-1β & prolyl hydroxylase-2) and selected genes of the angiogenic pathway (VEGF: vascular endothelial growth factor; VEGFR1/flt-1: VEGF receptor; ANG1: angiopoietin-1) were analyzed by real-time quantitative PCR. Total cellular RNA was reverse transcribed using the iScript cDNA synthesis kit (Biorad, Hercules, CA). Reactions without reverse transcriptase were included for individual RNAs as negative controls. Primers for the above genes were purchased from Real Time Primers (Elkins Park, PA) and the most stable reference genes phosphoglycerate kinase 1 and peptidylprolyl isomerase A were chosen from a panel of ten genes using geNorm software (Biogazelle, Belgium). Reactions were run in duplicate in a CFX Connect Real-Time PCR detection system (Biorad Lab Inc.) using SYBR-Green to measure DNA amplification. The instrument’s
software was used to calculate the threshold cycle (Ct) values for all the genes on the PCR Array. Fold change in gene expression for pair-wise comparison was processed on the Excel-based PCR Array Data Analysis software (SA Biosciences, MD) using the eq. 2-ΔΔCt by comparing the control group (RAS) to the other three groups (RAC, HS, HC).

Angiogenic protein analysis
Snap-frozen lung tissue was homogenized in ice-cold PBS (pH – 7.4) with protease inhibitors (Sigma, St. Louis, MO), spun, and the supernatant used for protein analysis by ELISA. The protein concentration was determined using the DC protein assay (BioRad, Hercules, CA). Protein analysis for HIF1α, HIF2α and HIF3α proteins (NovoTein Biosciences, Woburn, MA) and VEGF, VEGFR1 and ANG1 protein (R&D Systems, Minneapolis, MN) were performed by enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s protocol.

Cytokine measurements
Tumor necrosis factor α (TNF-α), Interferon γ (INF-γ) & interleukin-6 (IL-6) were measured in whole lung homogenates from cell-free supernatants on a postnatal day 5 in all the groups. Cytokine levels performed by ELISA technique (R&D systems, Minneapolis, MN), were normalized to total lung protein measured by Lowry assay.

Lung histopathology
The lungs were instilled with 10% buffered formalin at 25 cm H2O pressure in adult mice following tracheal cannulation. Instilled lungs were fixed overnight, serially dehydrated in ethanol and embedded in paraffin. Lung tissue cut into 5 μm full sections and stained with hematoxylin & eosin. We analyzed five slides/mouse and randomly analyzed 20 fields/slide for lung morphometry in all the groups. Alveolar development was evaluated by assessment of radial alveolar count (RAC) [26] and mean linear intercept (MLI) [27] by Aperio image analysis software (Leica Biosystems Inc., Buffalo Grove, IL). Assessment of secondary septal crest density performed by enzyme-linked immunosorbent assay (ELISA) according to manufacturer’s protocol.

Assessment of lung vessels
Lung vasculature was assessed on lung sections stained for collagen (trichrome staining) and endothelial cells (Von Willebrand factor immune histo-chemistry) at 12wks. Vessels that accompanied the airways were characterized as pulmonary arteries. Pulmonary arterioles of 20 - 100 μm in diameter were included and bronchioles excluded for analysis by a single operator blinded to the study groups. The number of blood vessels/high power field (× 200; 237,600 μm²) were counted successively in 20 HPFs per slide; the total blood vessel area (μm²) per HPF was also assessed in the same fields (200x) by Aperio image analysis software (Leica Biosystems Inc., IL, USA). Five lung sections were studied for each animal (n = ten pups per group).

Smooth muscle actin (α-SMA) immunohistochemistry
We first performed antigen retrieval of lung sections with citrate solution followed by blocking of non-specific binding with 10% goat serum in phosphate buffered saline (PBS). Lung sections incubated overnight with antibody to α-SMA (mouse monoclonal antibody, 1:100 dilution; Sigma-Aldrich Co. St Louis, MO) at 4 °C and rinsed with PBS. The sections were then incubated with peroxidase-labeled rabbit anti-mouse IgG (1:1000) for 30 min at 37 °C, washed with PBS and stained with 3,3’-diaminobenzidine (Sigma-Aldrich Co). Assessment of wall thickness was performed on α-SMA stained pulmonary vessels of 20 - 100 μm diameter at 400x magnification in all the four groups. We used Aperio image analysis software (Leica Biosystems Inc., Buffalo Grove, IL) to measure the cross-sectional area of the pulmonary arteriole. The surface area of the vessel wall assessed as a fraction of the total vessel area by the following formula, Area OVW – Area IVW/Area OVW; wherein, OVW – outer vessel wall, representing surface area of the cross-sectioned vessel; IVW – inner vessel wall, serving the surface area of the vessel lumen) [30].

Statistical analysis
Replicated 2-ΔΔCt values for each gene in the control group and the treatment group was used to calculate p values by student’s t-test. More than two group comparisons performed by analysis of variance (ANOVA) with Fisher’s post-hoc analysis when appropriate (Stat view, Abacus Concepts, Piscataway, NJ). Repeated measures ANOVA used to assess differences in body weight over time among groups. All values expressed as mean ± standard deviation (SD) of the mean with n representing the number of animals studied. A p value of < 0.05 was considered significant.

Results
Growth
There was no difference in body weight at 12wks between the two room air groups (RAS: 23.52 ± 1.86 g vs. RAC: 24.22 ± 2.92 g; Fig. 1a). However, postnatal caffeine
treatment significantly increased body weight in mice exposed to hyperoxia (HS: 21.77 ± 1.64 g vs. HC: 25.99 ± 3.77 g, p < 0.05 vs. HS group, ANOVA; Fig. 1a). Male mice gained significant body weight following postnatal caffeine administration. Mice exposed to room air (RA) and treated with caffeine had significantly higher body weight compared to both the saline groups (RAC: 25.79 ± 1.64 g & HS: 23.64 ± 0.56 g; p < 0.05 vs. RAS & HS groups, ANOVA; Fig. 1b). However, in mice exposed to hyperoxia, postnatal caffeine significantly increased body weight compared to all the other three groups (RAS: 23.89 ± 1.64 g; RAC: 25.79 ± 1.75 g; HS: 23.64 ± 0.56 g & HC: 27.82 ± 0.82 g, p < 0.01 vs. RAS, RAC & HS groups, ANOVA; Fig. 1b). There was no significant difference in body weight at 12wks in female mice with or without caffeine (Fig. 1c). We studied ten mice per group (RAS – 6 males, 5 females; RAC – 6 males, 4 females; HS – 5 males, 5 females; HC – 6 males, 4 females).

Gene expression
Gene expression was measured as fold change (FC) in mRNA expression relative to the control group (RAS group, FC of RAS group = 1, Table 1). Genes involved in the angiogenic pathway such as HIF-2α, PHD-2, and VEGF were significantly over-expressed in the room air caffeine and hyperoxia-saline groups compared to hyperoxia-caffeine group (Table 1). Expression of ANG-1 was considerably higher in room air mice exposed to caffeine (RAC group) compared to hyperoxia groups (Table 1). We observed no differences in the expression of HIF-1α, HIF-3α, HIF-1β or Flt-1 (VRGFR1) genes among the three groups.

Angiogenic proteins
Protein expression in the lung for HIF-1α, HIF-2α, HIF-3α, VEGF, FLT-1, and ANG1 was analyzed by enzyme immunoassay in 5-day old mice in all the four groups (Table 2). HIF-2α protein expression was significantly higher in the hyperoxia group compared to the other three groups (p < 0.05 vs. RAS & RAC groups, Fisher’s post-hoc test, ANOVA; Table 2). Expression of VEGF protein was significantly higher in the hyperoxia group compared to the other three groups (p < 0.05 vs. RAS, RAC & HC groups, Fisher’s post-hoc test, ANOVA; Table 2). Expression of angiogenic receptor, VEGFR1 (FLT-1) protein was significantly higher in the hyperoxia-caffeine group compared to both the room air groups (p < 0.05 vs. RAS & RAC groups, Fisher’s post-hoc test, ANOVA; Table 2). Expression of ANG-1 protein was significantly lower in the hyperoxia group compared to the other three groups (p < 0.05 vs. RAS, RAC & HC groups).
Table 1 Expression of selected angiogenic genes in the lung by qRT-PCR in newborn mice exposed to hyperoxia (95%O2) or room air and administered caffeine or saline

| Gene Symbol | Room Air-Caffeine (RAC) Group | Hyperoxia-Saline (HS) Group | Hyperoxia-Caffeine (HC) Group |
|-------------|-------------------------------|-----------------------------|------------------------------|
| Hif-1α      | 2.28 ± 1.05                   | 2.31 ± 0.33                 | 2.35 ± 0.85                  |
| Hif-2α      | 2.62 ± 0.87*                  | 2.67 ± 0.44*                | 1.52 ± 0.70                  |
| Hif-3α      | 2.83 ± 1.25                   | 1.72 ± 0.44                 | 1.64 ± 0.71                  |
| Hif-1β      | 1.77 ± 0.34                   | 1.65 ± 0.20                 | 1.51 ± 0.43                  |
| PHD-2       | 1.78 ± 0.30*                  | 1.89 ± 0.46*                | 1.00 ± 0.26                  |
| VEGF        | 2.00 ± 0.42*                  | 3.52 ± 0.66*                | 1.17 ± 0.34                  |
| Flt-1       | 2.71 ± 0.89                   | 2.44 ± 0.40                 | 1.93 ± 0.57                  |
| Ang-1       | 2.85 ± 1.26*                  | 1.89 ± 1.11                 | 0.89 ± 0.27                  |

The fold-change (FC) in gene expression is compared to the room air-saline (RAS) group (control group; FC in RAS = 1.0. (n = 8 pups in each group)

Values expressed as fold change ± SD compared to room air saline group. *p < 0.05 versus hyperoxia-caffeine group (Fisher’s post-hoc test, ANOVA); Hif-1α - Hypoxia-Inducible Factor-1α; Hif-2α - Hypoxia-Inducible Factor-2α; Hif-3α - Hypoxia-Inducible Factor-3α; Hif-1β - Hypoxia Inducible Factor-1β; PHD-2 - Prolyl Hydroxylase - 2 (EGLN1); VEGF - Vascular Endothelial Growth Factor; Flt-1 - VEGF Receptor 1; Ang-1 - Angiopoietin-1. Housekeeping genes - Phosphoglycerate kinase-1 (Pgk1); Peptidylprolyl isomerase A (Ppia)

Table 2 Protein expression of selected angiogenic proteins and cytokines in the lung measured by enzyme immunoassay (EIA) in newborn mice exposed to hyperoxia (95%O2) or room air and administered caffeine or saline

| Protein          | Room Air Saline Group (RAS) | Room Air Caffeine Group (RAC) | Hyperoxia Saline Group (HS) | Hyperoxia Caffeine Group (HC) |
|------------------|------------------------------|-------------------------------|-----------------------------|------------------------------|
| Hif-1α (pg)      | 230 ± 25                     | 215 ± 41                      | 250 ± 40                    | 253 ± 46                      |
| Hif-2α (ng)      | 0.232 ± 0.058                | 0.117 ± 0.008                 | 0.274 ± 0.055               | 0.464 ± 0.159*                |
| Hif-3α (pg)      | 6.96 ± 1.78                  | 5.99 ± 0.51                   | 7.60 ± 1.31                 | 6.05 ± 0.78                   |
| VEGF (pg)        | 55.5 ± 16.1                  | 64.6 ± 7.1                    | 177.5 ± 528**               | 92.8 ± 16.4                   |
| Flt-1 (pg)       | 2297 ± 1026                  | 1714 ± 85                     | 3364 ± 1590                 | 3866 ± 3080*                  |
| Ang-1 (ng)       | 522 ± 192                    | 664 ± 72                      | 258 ± 70†                   | 455 ± 70                      |
| TNF-α (pg/µg protein) | 0.350 ± 0.01               | 0.040 ± 0.01                  | 0.043 ± 0.02                | 0.045 ± 0.01                  |
| INFγ (pg/µg protein) | 0.098 ± 0.04              | 0.109 ± 0.03                  | 0.118 ± 0.04                | 0.134 ± 0.02                  |
| IL-6 (pg/µg protein) | 0.065 ± 0.02              | 0.062 ± 0.01                  | 0.081 ± 0.04                | 0.066 ± 0.01                  |

HIF & angiogenic proteins are expressed in ng or pg/mg protein of the lung (n = 8 pups in each group)

Values expressed as mean ± SD. *p < 0.05 vs RAC & RAS groups, **p < 0.05 vs RAS, RAC & HC groups, tp < 0.05 vs RAS, RAC & HC groups; (Fisher’s post-hoc test, ANOVA). Hif-1α - Hypoxia-Inducible Factor-1α; Hif-2α - Hypoxia-Inducible Factor-2α; Hif-3α - Hypoxia-Inducible Factor-3α; VEGF - Vascular Endothelial Growth Factor; Flt-1 - VEGF Receptor 1; Ang-1 - Angiopoietin-1; TNF-α: tumor necrosis factor alpha; INFγ: interferon gamma; IL-6: interleukin-6. HIF & angiogenic proteins are expressed as units/mg lung protein.

groups, Fisher’s post-hoc test, ANOVA; Table 2). There were no differences in protein expression of cytokines, such as TNF-α, INFγ, and IL-6 in the lung among the three groups (Table 2).

Histopathology

Mice exposed to postnatal hyperoxia demonstrate distended alveoli and enlarged air sacs at 12wks of age (Fig. 2e/f) when compared to relatively well-formed alveolar units in the RA groups (Fig. 2: a–d). Radial alveolar count (RAC), a unit of alveolar development was significantly lower in mice exposed to hyperoxia suggesting alveolar simplification (*p < 0.001 vs. RAS & RAC groups; Fisher’s post-hoc test, ANOVA; Fig. 2i). Mean linear intercept (MLI), a unit of alveolar enlargement was significantly higher in the hyperoxia group (*p < 0.001 vs. RAS & RAC groups, Fig. 2j). Postnatal caffeine augmented postnatal alveolarization and attenuated alveolar distension following hyperoxia (*p < 0.001 vs. HC group, ANOVA; Fig. 2i), suggesting caffeine may ameliorate hyperoxic lung injury in adult mice (Fig. 2g/h). A significant increase in secondary septal count (*p < 0.001 vs. HC group, Fisher’s post-hoc test, ANOVA; Fig. 3m) and septal length (*p < 0.001 vs. HC group; Fig. 3n) further strengthens the protective effects of postnatal caffeine administration. We demonstrate the beneficial effects of caffeine on all markers of alveolar development in both male and female mice (Fig. 2/Fig. 3). The findings advance the protective effects of caffeine against hyperoxia-induced lung injury and promoting lung growth.
Vessel data

Pulmonary blood vessels of 20-100 μm diameter were counted following von Willebrand factor immunohistochemistry and in trichrome stained lung sections in all the groups (Fig. 3). Blood vessel density expressed as a number of blood vessels per field studied was significantly higher in the hyperoxia group following postnatal caffeine, especially in male mice (\(\ast\ast p < 0.0001\) vs. RAS, RAC and HS groups, Fisher’s post-hoc test, ANOVA; Fig. 3o). Control female mice had significantly higher vessel density compared to RAC and HS groups (\(\ast p < 0.001\) vs. RAC and HS groups, Fisher’s post-hoc test, ANOVA; Fig. 3o); however, not different from hyperoxic mice that received postnatal caffeine. The surface area of blood vessels (237,600 μm²) was significantly higher in both male and female mice that received postnatal caffeine and hyperoxia (\(\ast\ast\ast p < 0.0001\) vs. RAS, RAC and HS groups, Fisher’s post-hoc test, Fig. 3q). The finding suggests that postnatal caffeine promotes microvascular growth along with alveolar growth.

Caffeine & Pulmonary Arterial Wall Thickness

Assessment of pulmonary vascular smooth muscle thickness was performed in lung sections by α-SMA immunohistochemistry in all the groups (Fig. 4). There was no difference in the mean diameter of the pulmonary arterioles analyzed among the groups (RAS: 48.7 ± 4.0 μm; RAC: 50.2 ± 2.9 μm; HS: 48.4 ± 6.3 μm; HC: 51.9 ± 1.7 μm). Pulmonary arterioles were thicker with smooth muscle hypertrophy in mice exposed to neonatal hyperoxia group at 12wks (Fig. 4e/f). Postnatal caffeine in mice exposed to hyperoxia significantly reduced vessel wall thickness at 12wks, especially in male mice (\(\ast p < 0.001\) vs. RAS & RAC groups; \(\ast\ast\ast p < 0.0001\) vs. HS group; Fisher’s post-hoc test, ANOVA; Fig. 4i). Arterial wall thickness was not different among the groups in female mice. The effects of caffeine on pulmonary vascular remodeling and consequently on the development of pulmonary hypertension is gender specific with protective and beneficial effects in male mice.
Discussion

Caffeine therapy for apnea of prematurity reduces the incidence of bronchopulmonary dysplasia in VLBW infants [5]. Although the mechanisms of the possible protective actions of caffeine are not apparent, potential effects on the endothelial cells [31, 32] and the vascular smooth muscle [33] in addition to the antagonism of the adenosine receptors [15] partly explain its beneficial effects. We have shown that caffeine by modulating the HIF-angiogenesis pathway, promotes alveolarization and angiogenesis with beneficial effects on the pulmonary vasculature.

Hypoxia-inducible factors (HIFs) are transcription factors that regulate the downstream expression of genes that mediate the response to hypoxia. Constant expression and degradation of HIF by PHD-2 results in not only a steady state concentration but also in a short half-life. In our study, both caffeine and hyperoxia by themselves significantly increased expression of HIF-2α and angiogenic genes VEGF and ANG-1. Figure 5 illustrates the potential role of caffeine in the modulation and regulation of HIF induced angiogenesis. Reactive oxygen species, including H$_2$O$_2$, play a significant role in the upregulation of HIF pathway by several mechanisms, including interactions with PHD complex co-factors such as ferrous ion, ascorbate, and succinate [34]. Other intermediates such as nitric oxide, specific microRNAs and transcriptional and post-translational modifications mediate ROS mediated HIF-1 signaling [35]. Studies have shown a paradoxical higher level of HIF-1α in the presence of hyperoxia [36, 37]. Low concentrations of caffeine actively induce VEGF expression via activation of HIF-1α [38]. Transcript levels of HIF are of little predictive value concerning protein expression [39], as this can be influenced by protein half-life, post-translational changes, experimental conditions, and by the activity of prolyl hydroxylase isoforms. However, postnatal caffeine significantly induced HIF-2α protein in the lung in mice exposed to hyperoxia. HIF-2α could contribute to the expression of angiogenic genes seen in our study.

Angiogenic proteins, VEGF and its receptor, VEGFR1 was higher in both the hyperoxia groups; however, the receptor protein was significantly higher in the hyperoxia-exposed mice that received postnatal caffeine. While some animal studies have reported a relative decrease in lung VEGF mRNA and protein in response to hyperoxia [40–42],
others have shown an increase in VEGF protein [43]. The variability in expression may be related to the stage of lung development in an animal model, the timing of the VEGF mRNA and its protein measurement and the variability of the VEGF isoforms measured [44]. The VEGF assay measured both 120 and 164 isoforms, and the expression of both proteins decreases with progression of lung development with low levels in adult lung. Mice in the hyperoxia-caffeine group had higher HIF-2α protein and VEGFR1 receptor density with relatively normal VEGF protein levels in the lung. Mice exposed to hyperoxia alone had significantly low levels of ANG1, a protein that plays a critical role in mediating reciprocal interactions between the endothelium, surrounding matrix, and the mesenchyme. ANG1 protein enhances the effect of VEGF, contributing to blood vessel maturation and vascular remodeling. Caffeine by increasing ANG1 in the lung may act synergistically with VEGF in ameliorating the abnormal vascular response during the early stages of lung injury. Caffeine by modulating the levels of VEGF and angiopoietin via the HIF pathway not only alters the abnormal vascular responses but may also enhance alveolar and microvascular development in the lung in the presence of hyperoxia.

Vessel density and vessel surface area were higher following postnatal caffeine in hyperoxia-exposed mice. An increase in vasculature may be secondary to higher expression of angiogenic proteins VEGFR1 and ANG1 in the HC group. An increase in vessel wall thickness following neonatal hyperoxia may suggest developing pulmonary hypertension in the context of hyperoxic lung injury [45]. However, postnatal caffeine attenuated lung injury with a significant decrease in vessel wall thickness following neonatal hyperoxia. The effects of caffeine on vascular remodeling is gender specific, with substantial benefits in male mice. However, female mice that received postnatal caffeine may have had minimal vascular remodeling compared to RA controls. Sex differences in systemic blood pressures are evident in young adults and continue through adulthood, with men more likely to be hypertensive than women regardless of race or

Fig. 4 Assessment of vessel wall thickness at 12wks by α-smooth muscle actin immunohistochemistry of lung sections (100x: a/c/e/g; 400x: b/d/f/h; room air saline (RAS): A/B; room air caffeine (RAC): c/d; hyperoxia saline (HS): e/f; hyperoxia caffeine (HC): g/h). Scale: 200μm (100x), 60μm (400x). Thick arrows (400x) correspond to the same histologic location as thin arrows (100x) of the same group. Demonstrated vessels are of a 30-50μm diameter in all the four groups. Pulmonary arterial vessel wall thickness was greater in the hyperoxia group suggestive of smooth muscle hypertrophy (i: *p < 0.001 vs. RAS; Fisher’s post-hoc test, ANOVA). Caffeine administration attenuated vessel wall thickness, especially in male mice at 12 weeks of age (**p < 0.0001 vs HS group, Fisher’s post-hoc test, ANOVA; i), suggesting it may have beneficial effects on the pulmonary vasculature (Open box plots – RA groups; shaded box plots – hyperoxia groups) (n = ten mice/group)
ethnicity [46], and this may be related to the protective effects of sex hormones in females [46]. Induction of HIF-2α and ANG1 may play an essential role in microvascular stability and vascular remodeling. Caffeine-induced endothelial-dependent relaxation mediated by nitric oxide, endothelial-independent relaxation mediated by phosphodiesterase inhibition [47] and adenosine receptor blockade [15] among other smooth muscle effects [33] is additional contributors to the beneficial effects of caffeine on the vascular smooth muscle.

Improvements in lung morphometry measurements, including secondary septal length, indicate the protective effect of neonatal caffeine administration on postnatal lung growth in mice exposed to hyperoxia in both male and female mice. Caffeine may modulate the dynamic interrelationships between VEGF and ANG1, two critical regulators of pulmonary vascular development early in the evolution of lung injury, contributing to improved alveolarization in adult mice. However, the protective effects of caffeine on alveolar development are debatable with several studies suggesting an adverse effect on alveolar development [10, 14] and others signifying beneficial effects [12, 13, 48]. Even though inflammatory cytokines studied in the lung were unremarkable, caffeine may either worsen inflammation by increasing neutrophil chemoattractant, CXCL-1 [14] or may have a protective effect on lung inflammation [11, 13]. An increase in eNOS activity and tetrahydrobiopterin levels may contribute to improved alveolar structure and angiogenesis in immature lungs [48]. Improvements in lung structure relating to alveolar growth and attenuation of vascular remodeling may add to higher body weight, especially in adult male mice following hyperoxia. However, programming of offspring towards excess growth may occur from alterations in the hypothalamic-pituitary-adrenocortical axis [49] or changes in adenosine receptor expression [50] that play a key role in growth and development following prenatal caffeine [51].

Caffeine may affect multiple pathways and gene expression, and the limitation of the study is its focus on angiogenesis and lung development. Results of protein and mRNA expression of HIF-1 and angiogenic genes following hyperoxia may be difficult to extrapolate to lung growth at 12 weeks of age. Also, as lung growth and gene expression are developmentally regulated, assessment at transitional time points would have been useful. Beneficial effects of caffeine on the pulmonary

**Fig. 5 Illustration of potential modulation of HIF regulation by caffeine.** Stabilization of HIF1α/2α determined by several factors including oxygen, the activity of PHD complex and its co-factors and reactive oxygen species. HIF-1α/2α activates multiple genes involved in glycolysis, angiogenesis, vascular remodeling, cell proliferation, and erythropoiesis via nuclear transcription. Higher expression of VEGFR1 and angiopoietin-1 along with vascular remodeling following caffeine administration may normalize lung histology seen in hyperoxia-induced lung injury. Hydroxylation of prolyl hydroxylase complex inactivates HIF-1α/2α followed by ubiquitination and proteasome degradation. HSL: hormone-sensitive lipase; 2OG: 2-oxoglutarate; ROS: reactive oxygen species; PHD: prolyl hydroxylase; HIF: hypoxia inducible factor; HRE: hypoxia response element; VEGFR1: vascular endothelial growth factor receptor-1; Ang-1: angiopoietin-1; BPD: bronchopulmonary dysplasia; AOE – antioxidant enzyme activity; ETC – electron transport chain; PTP: permeability transition pore (copyright – Vasantha HS Kumar, MD).
vasculature could not be confirmed by either pulmonary hemodynamic studies or heart remodeling indices. Caffeine acts on tissues everywhere in the body by inhibiting the adenine receptors and increases the respiratory drive, respiratory rate, diaphragm function, and diuresis, among other effects [52, 53]. Postnatal caffeine treatment improves pulmonary function in mid-childhood [54]. We did not assess the impact of caffeine on lung function. Caffeine dose of 20 mg/kg in mice is equivalent to 2.4 mg/kg in humans [55]. The treatment administered is well below the recommended dose of 20 mg/kg loading dose followed by 5-10 mg/kg as a maintenance dose in neonates for apnea of prematurity [5]. Most of the animal studies with caffeine have used doses similar to ours for more extended periods (10–21 days). Caffeine for 4 days is the shortest duration of administration for assessment of lung histology and morphometry. Despite low dosage of caffeine, we demonstrate beneficial effects on angiogenesis, alveolarization, and vascular remodeling in adult mice. Even small doses of postnatal caffeine may have beneficial effects on lung growth and function over long-term with benefits apparent in male mice. Caffeine is extensively used in premature neonates in the treatment of apnea of prematurity and to decrease the incidence of BPD. Although administered in large doses for long periods in newborns, the toxic effects of caffeine are infrequent. We have reported the beneficial effects of postnatal caffeine on lung morphometry and microvascular development with the potential to attenuate pulmonary vascular remodeling in male mice. Caffeine may modulate HIF-induced angiogenesis in mice exposed to hyperoxia, contributing to improved lung growth in adult mice.

Abbreviations
ANG1: Angiopoietin-1; BPD: Bronchopulmonary dysplasia; ELISA: Enzyme-linked immunosorbent assay; eNOS: Endothelial nitric oxide synthase; HIF: Hypoxia-inducible factor; HPF: High power field; IL6: Interleukin-6; INF-γ: Interferon γ; PCR: Polymerase chain reaction; PHD-2: Prolyl hydroxylase-2; RA: Room air; RAC: Radial alveolar count; TGF-β: Transforming growth factor-β; TNF-α: Tumor necrosis factor α; VEGF: Vascular endothelial growth factor; VEGFR1/FLT1: Vascular endothelial growth factor receptor-1; VLBW: Very low birth weight

Acknowledgments
Not applicable

Authors’ contributions
VD and VK conceived and designed the study. HW and VD were responsible for breeding, mice experiments & immunohistochemistry; LN performed gene expression, protein, and cytokine analysis; VK supervised the study; VD drafted the initial manuscript; VK revised the manuscript. All authors read and approved the final manuscript.

Funding
The study was supported in part by Marshall Klaus Grant from the American Academy of Pediatrics to Vikramaditya Dumpa (VD), Department of Pediatrics, University at Buffalo, Buffalo, NY.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study approved by the Institutional Animal Care and Use Committee of the University at Buffalo, Buffalo, NY (IACUC#PED24116N).

Consent for publication
Not applicable (animal study)

Competing interests
The authors declare that they have no competing interests.

Author details
1Winthrop University Hospital, Mineola, NY, USA. 2Division of Neonatology, Department of Pediatrics, John R Oishei Children’s Hospital, University at Buffalo, 1001 5th Floor Main Street, Buffalo, NY 14203, USA.

Received: 22 September 2018 Accepted: 23 July 2019
Published online: 30 July 2019

References
1. Jobe AH. The new bronchopulmonary dysplasia. Curr Opin Pediatr. 2011;23(2):167–72.
2. Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007;175(10):978–85.
3. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol. 2006;30(4):227–32.
4. Greenough A. Long-term pulmonary outcome in the preterm infant. Neonatology. 2008;95(4):324–7.
5. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21.
6. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893–902.
7. Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Azstalos EV, et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307(3):275–82.
8. Rhein LM, Dobson NR, Darnall RA, Corwin MJ, Heeren TC, Poets CF, et al. Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial. JAMA Pediatr. 2014;
9. Doyle LW, Ranganathan S, Cheong JY. Neonatal caffeine treatment and respiratory function at 11 years in children <1251 g birth weight. Am J Respir Crit Care Med. 2017;
10. Rath P, Nardiello C, Surate Solaligue DE, Agius R, Huhn S, et al. Caffeine administration modulates TGF-beta signaling but does not attenuate blunted alveolarization in a hypoxia-based mouse model of bronchopulmonary dysplasia. Pediatr Res. 2017;81(5):795–805.
11. Weichelt U, Cey R, Schmitz T, Strauss E, Sifflinger M, Buehrer C, et al. Prevention of hypoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J. 2013;41(4):966–73.
12. Teng RJ, Jing X, Michalkiewicz T, Afalaya AJ, Wu TJ, Konduri GG. Attenuation of endoplasmic reticulum stress by caffeine ameliorates hyperoxia-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2017;312(5):L586–L98.
13. Nagatomo T, Jimenez R, Richter J, De Baere S, Vanoirbeek J, Naulaers G, et al. Caffeine prevents hyperoxia-induced functional and structural lung damage in preterm rabbits. Neonatology. 2016;109(4):274–81.
14. Dayanlim S, Lopez B, Maisonet TM, Grewal S, Londehe VA. Caffeine induces alveolar apoptosis in the hyperoxia-exposed developing mouse lung. Pediatr Res. 2014;75(3):395–402.
15. Fredholm BB, Uzerman AP, Jacobson KA, Klitz KN, Linden J. International Union of Pharmacology. XXXI. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53(4):527–52.
16. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Vojno-Yasenetskaya T, et al. Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circ Res. 2002;90(5):S31–8.
17. Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res. 2003;92(5):485–92.
18. Ouyang X, Ghanî A, Malik A, Wilder T, Colegio OR, Flavell RA, et al. Adenosine is required for sustained inflammation activation via the a2 receptor and the HIF–1alpha pathway. Nat Commun. 2013;4:2909.
19. Merighi S, Benini A, Miranda P, Gessi S, Varani K, Simioni C, et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol. 2007;72(2):395–406.
20. Jakkula M, Le Cas TD, Gebs S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279(3):L600–7.
21. McGrath-Morrow SA, Cho C, Cho C, Zhen L, Hicklin DJ, Tuder RM. Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development. Am J Respir Cell Mol Biol. 2005;32(5):420–7.
22. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604–13.
23. Hato T, Kimura Y, Morisada T, Koh GY, Miyata K, Tabata M, et al. Angiopoietins contribute to lung development by regulating pulmonary vascular network formation. Biochem Biophys Res Commun. 2009;381(2):218–23.
24. Yu AF, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 1995;269(5 Pt 1):H1608–26.
25. O'Reilly MA, Marr SH, Yee M, McGrath-Morrow SA, Lawrence BP. Neonatal hypoxia enhances the inflammatory response in adult mice infected with influenza virus. Am J Respir Crit Care Med. 2008;177(10):1103–10.
26. Emeiry JL, Mithal A. The number of alveoli in the terminal respiratory unit of adult mice. Pediatr Pulmonol. 2016;51(11):1131
27. Emery JL, Mithal A. Neonatal hyperoxia increases airway reactivity and inflammation in adult mice. Pediatr Pulmonol. 2016;51(11):1131–4.
28. Datta A, Kim GA, Taylor JM, Gugino SF, Farrow KN, Schumacker PT, et al. Mouse lung development and NOX1 induction during hypoxia are developmentally regulated and mitochondrial ROS dependent. Am J Physiol Lung Cell Mol Physiol. 2015;309(4):L369–77.
29. Nicola T, Hargood IS, James ML, Macowen MW, Williams TA, Hewitt MM, et al. Loss of Thy-1 inhibits alveolar development in the newborn mouse lung. Am J Physiol Lung Cell Mol Physiol. 2009;296(5):L178–80.
30. Kumar VH, Lakshminrusimha S, Kishkurno S, Paturi BS, Gugino SF, Nielsen L, et al. Neonatal hypoxia increases airway reactivity and inflammation in adult mice. Pediatr Pulmonol. 2016;51(11):1311–41.
31. Umemura T, Ueda K, Nithioka K, Hijaka T, Takemoto H, Nakamura S, et al. Effects of acute administration of caffeine on vascular function. Am J Cardiol. 2006;98(11):1538–41.
32. Zucchi R, Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev. 1997;49(1):1–51.
33. Echeverri D, Montes FR, Cabrera M, Galan A, Prieto A. Caffeine’s vascular mechanisms of action. Int J Vasc Med. 2010;2010:834060.
34. Qutub AA, Popel AS. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol. 2008;28(16):5106–19.
35. Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem. 2015;116(5):696–703.
36. Benderro GF, Sun X, Kuan Y, Lamanna JC. Decreased VEGF expression and microvascular density, but increased HIF-1 and 2alpha accumulation and EPO expression in chronic moderate hypoxia in the mouse brain. Brain Res. 2012;1471:46–55.
37. Terraneo L, Virgili E, Careetti A, Bianchetti P, Samaja M. In vivo hypoxia induces hypoxia-inducible factor-1alpha overexpression in LNCaP tumors without affecting the tumor growth rate. Int J Biochem Cell Biol. 2014;51:65–74.
38. Kako S, Funakoshi-Tago M, Kobata K, Tamura H. Coffee induces vascular endothelial growth factor (VEGF) expression in human neuroblastoma SH-SY5Y cells. Nutr Neurosci. 2017;20(6):336–42.